Madrigal Pharmaceuticals (MDGL) Other Operating Expenses (2016 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Other Operating Expenses of $40.0 million for Q2 2026, up 341.33% year-over-year from $9.1 million in Q2 2025, and up 49.02% quarter-over-quarter from $26.8 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Other Operating Expenses (2016 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Other Operating Expenses for 4 consecutive years, with $40.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Operating Expenses rose 341.33% year-over-year to $40.0 million; the TTM figure through Jun 2026 stood at $109.4 million (up 1281.09% YoY), while the FY2025 annual figure was $56.1 million, up 800.82% from the prior year.
- Other Operating Expenses climbed to $40.0 million in Q2 2026 per MDGL's latest filing, from $26.8 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $40.0 million in Q2 2026 and bottomed at -$7.8 million in Q4 2024.
- Historically, Other Operating Expenses has averaged $13.1 million across 3 years, with a median of $9.1 million in 2025.
- Annual changes were most pronounced in 2025 — Other Operating Expenses surged 1325.31% — and 2026, when it surged 341.33%.
- Madrigal Pharmaceuticals' Other Operating Expenses stood at -$7.8 million in 2024, then jumped by 413.15% to $24.4 million in 2025, then jumped by 63.64% to $40.0 million in 2026.
- Business Quant data shows MDGL's Other Operating Expenses at $40.0 million in Q2 2026, $26.8 million in Q1 2026, and $24.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.01 Mn |
| Mar 31, 2026 | 26.85 Mn |
| Dec 31, 2025 | 870.56 Mn |
| Sep 30, 2025 | 18.12 Mn |
| Jun 30, 2025 | -241.87 Mn |
| Mar 31, 2025 | 4.51 Mn |
| Dec 31, 2024 | -679.58 Mn |
| Sep 30, 2024 | -174.18 Mn |
| Jun 30, 2024 | -175.90 Mn |
| Mar 31, 2024 | -152.04 Mn |
| Jun 30, 2016 | 91,000.00 |